Stifel bumped up its price target for Okta, Inc. (NASDAQ:OKTA) to $130 from $120. The firm also reiterated a Buy rating on ...

On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX).

and on Friday a three-person arbitration panel ruled Stifel Nicolaus & Co. Inc. pay $7 million in legal costs of advisors who left the firm in 2023 and then were sued by the firm. It’s the ...

The St. Louis-based financial services giant has inked what officials called an "unprecedented" extension of its sponsorship ...

The competing legal strategies appear contrary to Stifel’s public statements about defending its structured notes’ tactics.